Anumana is a company that is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Pulse 2.0 interviewed Anumana CEO Maulik Nanavaty to learn more about the company.
Anumana: Interview With CEO Maulik Nanavaty About The AI-Driven Health Technology Company
Related Articles
Anumana Named to Fast Company’s 2026 Most Innovative Companies Awards
Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support CAMBRIDGE, Mass., March 24, 2026—Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named…March 24, 2026
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…May 23, 2022
Anumana earns first full FDA clearance for AI to detect low ejection fraction
Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine…October 05, 2023
Anumana Joins Accelerating Medicines Partnership Heart Failure Program to Advance ECG-AI® Research
Program provides access to real-world data to refine AI algorithms for earlier detection of complex heart conditionsOctober 24, 2024